Clinical trial
Safety and Tolerability Study of FolateImmune in Combination With Cytokines in…
NCT00329368 · Endocyte, Industry · Completed
Key facts
| NCT number | NCT00329368 |
|---|---|
| Title | Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer |
| Official title | A Phase I Study of EC90 With GPI-0100 Adjuvant Followed by EC17 With Cytokines (Interleukin-2 [IL-2] and Interferon-alpha [IFN-alpha]) in Patients With Refractory or Metastatic Cancer |
| Lead sponsor | Endocyte, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Biological, Drug |
| Interventions | EC90 (KLH-FITC), GPI-0100, EC17 (Folate-FITC), Interleukin-2, Interferon-alpha |
| Enrollment | 13 |
| Start date | Sep 1, 2005 |
| Primary completion | Dec 1, 2007 |
| Completion | Jun 1, 2008 |
| First posted | May 24, 2006 |
| Last update posted | Mar 9, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: